Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Current Leases (2019 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Current Leases for 7 consecutive years, with $12.0 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 20.0% to $12.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.0 million through Dec 2025, up 20.0% year-over-year, with the annual reading at $12.0 million for FY2025, 20.0% up from the prior year.
  • Current Leases for Q4 2025 was $12.0 million at Ultragenyx Pharmaceutical, down from $12.1 million in the prior quarter.
  • The five-year high for Current Leases was $12.8 million in Q1 2024, with the low at $9.4 million in Q1 2021.
  • Average Current Leases over 5 years is $11.3 million, with a median of $11.5 million recorded in 2022.
  • The sharpest move saw Current Leases surged 37.42% in 2021, then fell 20.6% in 2024.
  • Over 5 years, Current Leases stood at $11.1 million in 2021, then increased by 6.44% to $11.8 million in 2022, then rose by 6.93% to $12.6 million in 2023, then dropped by 20.6% to $10.0 million in 2024, then grew by 20.0% to $12.0 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $12.0 million, $12.1 million, and $11.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.